NCT04976192View on ClinicalTrials.gov

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

PHASE3CompletedINTERVENTIONAL
Enrollment

608

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

April 5, 2024

Study Completion Date

April 5, 2024

Conditions
Chronic Urticaria
Interventions
COMBINATION_PRODUCT

TEV-45779

TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe

COMBINATION_PRODUCT

XOLAIR® Injection

XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.

Trial Locations (9)

32751

10014, Maitland

33014

10005, Miami

33134

10012, Coral Gables

33613

10009, Tampa

33765

Site 10001, Clearwater

34744

10006, Kissimmee

48084

10007, Troy

84117

10004, Salt Lake City

93301

10008, Bakersfield

All Listed Sponsors
collaborator

Teva Pharmaceuticals Development, Inc.

UNKNOWN

lead

Teva Pharmaceuticals USA

INDUSTRY

NCT04976192 - Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria | Biotech Hunter | Biotech Hunter